Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.
Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback